Trial · NCT02819635
Adverse events1,924
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,924
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | SS1: Placebo | 3 | 46 | 3 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS1: Upadacitinib 7.5 mg | 0 | 47 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS1: Upadacitinib 15 mg | 3 | 49 | 3 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS1: Upadacitinib 30 mg | 4 | 117 | 4 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS1: Upadacitinib 45 mg | 1 | 123 | 1 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS2: Placebo | 9 | 155 | 9 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS2: Upadacitinib 45 mg | 8 | 319 | 8 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS2: Placebo/Upadacitinib 45 mg | 5 | 85 | 5 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | 1 | 59 | 1 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS3: Placebo | 20 | 385 | 24 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS3: Upadacitinib 7.5 mg | 1 | 20 | 2 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS3: Upadacitinib 15 mg | 11 | 323 | 12 |
| other | ANAEMIA | Blood and lymphatic system disorders | SS3: Upadacitinib 30 mg | 7 | 316 | 7 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS1: Placebo | 0 | 46 | 0 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS1: Upadacitinib 7.5 mg | 0 | 47 | 0 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS1: Upadacitinib 15 mg | 0 | 49 | 0 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS1: Upadacitinib 30 mg | 1 | 117 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS1: Upadacitinib 45 mg | 1 | 123 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS2: Placebo | 1 | 155 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | SS2: Upadacitinib 45 mg | 6 | 319 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02819635/events